Oestrogen as a reticuloendothelial stimulant in patients with cancer.
Stimulation of reticuloendothelial activity may benefit patients with cancer. Oestrogenic compounds are known to stimulate reticuloendothelial phagocytic activity in animals and a similar effect is demonstrated in patients.The depression of reticuloendothelial phagocytic activity which follows radiotheraphy in the treatment of cancer can be prevented by the simultaneous administration of stilboestrol. Possibly this could be associated with a more favourable response to therapy, and a controlled trial is needed to establish this.
D001943:Breast Neoplasms / Q000188:drug therapy; D001984:Bronchial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D012157:Mononuclear Phagocyte System / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010587:Phagocytosis / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013268:Stimulation, Chemical; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D004967:Estrogens; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; D004964:Estriol